Insulin Glargine Injection Gansulin®R Human Insulin Injection Gansulin®R Human Insulin Injection Gansulin®N Isophane Protamine Human Insulin Injection Gansulin®N Isophane Protamine Human Insulin Injection Gansulin®30R Mixed Isophane Protamine Human Insulin Injection (30R) ...
Tonghua Dongbao values both in-house R&D and external cooperation. To facilitate the development of new products, we have set up R&D offices across in Beijing, Shanghai, Hangzhou, and Tonghua for new drug development, research results commercialization, domestic and international drug registration, ov...
Tonghua Dongbao's 1H23 earnings were in line with expectations. Overall, insulin products showed good growth momentum, with continued market share gains for second- and third-generation insulins. The diabetes and gout pipelines progressed in an orderly manner, and the internationalization process adva...
small volume injections, traditional Chinese medicine, active pharmaceutical ingredients (recombinant human insulin) and bio-engineering products. The company also produces building materials such as plastic steel windows. Tonghua Dongbao Pharmaceutical was founded on December 28, 1992 and is headquartered in...
继续沿抚通高速行驶24.5公里,朝抚顺,沈阳方向,直行 继续沿抚通高速行驶13.9公里,朝抚顺,沈阳方向,直行 继续沿抚通高速行驶3.7公里,朝抚顺,沈阳方向,直行 继续沿抚通高速行驶17.2公里,朝抚顺,沈阳方向,直行 继续沿抚通高速行驶17.9公里,朝抚顺,沈阳方向,直行 继续沿抚通高速行驶9.3公里,直行 继续沿抚通高速行驶3.4...
通化东宝是一家糖尿病治疗药物研发商,产品主要针对糖尿病患者,具体包括常规胰岛素(甘舒霖R)、中效胰岛素(甘舒霖N)、30/70混合重组人胰岛素注射液(甘舒霖30R)等;同时还为用户提供血糖仪、 GM700血糖监测管理系统、采血笔及试纸等产品。 查看更多企业信息> 修改信息 关注 认领企业 委托联系 维护信息 相关企业 关于...
Ransulin-N inj 3 mL, 3 mL, Tonghua Dongbao Pharma, Insulin PreparationsRansulinN inj mLTonghua Dongbao PharmaRansulin-N
HOME ABOUT PRODUCTS NEWS CONTACT CASE CASE Current Location: HOME > CASE Tonghua Dongbao Pharmaceutical Co., Ltd. (Freezer)Facebook LinkedIn E-mailsyl-compressor@syl-inter.com Fax+86-24-87440208 Phone+86-24-83501123 辽ICP备16004332号-2...
药物总览提供了重组人胰岛素(通化东宝)Recombinant human insulin (Tonghua Dongbao Pharmaceutical)相关药品信息, 涵盖了药品临床前,临床阶段,注册,上市等药品全生命周期研发数据, 通过表格与图表等形式多维度地帮助帮助用户筛选与查看
Today, Tonghua Dongbao provides the world with five novel drugs, including three for diabetes and two for gout. Among them, first subject enrolled in Phase I clinical trial on first Chinese-made dual-target inhibitor for gout (THDBH151 Tablets) in May 2023, novel URAT1 inhibitor for gout mee...